Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

NCT ID: NCT06878859

Last Updated: 2026-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-28

Study Completion Date

2029-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression - Major Depressive Disorder Cannabis Use Disorder Mental Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amplification of Positivity - Cannabis Use (AMP-C)

Group Type EXPERIMENTAL

Amplification of Positivity - Cannabis Use (AMP-C)

Intervention Type BEHAVIORAL

AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.

Symptom Tracking

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amplification of Positivity - Cannabis Use (AMP-C)

AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged ≥ 18 years
* Resides in the United States
* Able to read and understand English and willing to provide informed consent/comply with the study protocol
* Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)
* Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
* Current elevated anhedonia, as indicated by the PHQ-9
* Interest in receiving treatment for their cannabis use and depression
* Meet criteria for current MDD and CUD per the DSM-5

Exclusion Criteria

* History of a psychotic disorder or bipolar disorder type I/II
* Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale
* Current psychotherapy engagement
* Changes in psychotropic medication within six weeks of the start of study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

Massachusetts General Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amanda C. Collins

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shirley Wu, BS

Role: primary

617-724-3532

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025p000583

Identifier Type: -

Identifier Source: org_study_id

1K23DA062034

Identifier Type: NIH

Identifier Source: secondary_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Precision Care for Major Depressive Disorder
NCT06580041 ENROLLING_BY_INVITATION PHASE4
Rhythm and Depression
NCT02857036 UNKNOWN NA